Open-label Study With Bosentan in Interstitial Lung Disease

2014-07-23 21:45:12 | BioPortfolio


This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Interstitial Lung Disease




University of Alabama
United States





Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:45:12-0400

Clinical Trials [1691 Associated Clinical Trials listed on BioPortfolio]

Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study

Over time, patients with fibrosing or interstitial lung disease (ILD) can develop high lung blood pressures (pulmonary hypertension), and this is associated with poorer prognosis and survi...

BUILD 3: Bosentan Use in Interstitial Lung Disease

BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is ...

Sequential Changes of Serum KL-6 Predict Progression in Interstitial Lung Disease

Interstitial lung disease is a chronic progressive fibrosis lung disease that with a highly variable clinical process.thence it is significant for the patient to search a convenient and ac...

Interstitial Lung Disease Registry Construction

The purpose of this study is investigating the clinical course, treatment course, and prognosis of patients with interstitial lung disease.

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently th...

PubMed Articles [17906 Associated PubMed Articles listed on BioPortfolio]

Morphologic Aspects of Interstitial Pneumonia With Autoimmune Features.

- Interstitial lung disease, a common complication observed in several connective tissue diseases, causes significant morbidity and mortality. Similar to individuals with connective tissue diseases, a...

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab.

Compared to conventional cytotoxic chemotherapy, immune checkpoint inhibitors have shown a significant efficacy in the treatment of lung cancer. Although interstitial lung disease (ILD) is an importan...

Does Systemic Sclerosis-Associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.

Previous studies have suggested that interstitial lung disease (ILD) progresses most rapidly early in the course of systemic sclerosis-associated (SSc)-ILD and that SSc-ILD is often more stable or eve...

Increasing Opportunity for Lung Transplant in Interstitial Lung Disease with Pulmonary Hypertension.

Extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplantation (BTT) for end-stage interstitial lung disease (ILD) and pulmonary hypertension (PH) has varying results based on ECMO con...

Lung ultrasound surface wave elastography for assessing interstitial lung disease.

Our goal is to translate lung ultrasound surface wave elastography (LUSWE) for assessing patients with interstitial lung disease (ILD) and various connective tissue diseases including systemic scleros...

Medical and Biotech [MESH] Definitions

A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.

A form of pneumoconiosis caused by inhalation of asbestos fibers which elicit potent inflammatory responses in the parenchyma of the lung. The disease is characterized by interstitial fibrosis of the lung, varying from scattered sites to extensive scarring of the alveolar interstitium.

A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.

An interstitial lung disease of unknown etiology, occurring between 21-80 years of age. It is characterized by a dramatic onset of a "pneumonia-like" illness with cough, fever, malaise, fatigue, and weight loss. Pathological features include prominent interstitial inflammation without collagen fibrosis, diffuse fibroblastic foci, and no microscopic honeycomb change. There is excessive proliferation of granulation tissue within small airways and alveolar ducts.

A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis.

More From BioPortfolio on "Open-label Study With Bosentan in Interstitial Lung Disease"

Quick Search


Relevant Topic

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Searches Linking to this Trial